Floatz logo

Dual Target Car-T Cell Therapy

B ALL

Shenzhen University General HospitalCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the B ALL cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
FILGRASTIM
University of Washington
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Dual Target Car-T Cell Therapy is also rated in:

Dual-target CAR-T CellsDormant
CCC
Indicative ·
48 / 100
View asset →
lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →